company background image
NPHC logo

Nutra Pharma OTCPK:NPHC Stock Report

Last Price

US$0.0001

Market Cap

US$706.5k

7D

0%

1Y

900.0%

Updated

23 Apr, 2024

Data

Company Financials

NPHC Stock Overview

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States.

NPHC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Nutra Pharma Corp. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nutra Pharma
Historical stock prices
Current Share PriceUS$0.0001
52 Week HighUS$0.0017
52 Week LowUS$0.000001
Beta0
1 Month Change0%
3 Month Changen/a
1 Year Change900.00%
3 Year Change-98.67%
5 Year Change-75.00%
Change since IPO-99.83%

Recent News & Updates

Recent updates

Shareholder Returns

NPHCUS BiotechsUS Market
7D0%1.5%1.2%
1Y900.0%1.1%24.7%

Return vs Industry: NPHC exceeded the US Biotechs industry which returned -3.7% over the past year.

Return vs Market: NPHC exceeded the US Market which returned 19.3% over the past year.

Price Volatility

Is NPHC's price volatile compared to industry and market?
NPHC volatility
NPHC Average Weekly Movementn/a
Biotechs Industry Average Movement11.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: NPHC's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine NPHC's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000n/aMichael Flaxwww.nutrapharma.com

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, non–narcotic, non–addictive, and over–the–counter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and anti–inflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain.

Nutra Pharma Corp. Fundamentals Summary

How do Nutra Pharma's earnings and revenue compare to its market cap?
NPHC fundamental statistics
Market capUS$706.47k
Earnings (TTM)US$7.11m
Revenue (TTM)US$247.77k

0.0x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NPHC income statement (TTM)
RevenueUS$247.77k
Cost of RevenueUS$181.24k
Gross ProfitUS$66.53k
Other Expenses-US$7.05m
EarningsUS$7.11m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did NPHC perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.